Loading

Please wait...

Perphenazine

Perphenazine Prescription
Generic Name: perphenazine (per FEN a zeen)
Brand Name: Trilafon
Physician reviewed perphenazine patient information - includes perphenazine description, dosage and directions.

Average Savings for perphenazine (generic): 9.02%
  • Prescription Settings
  • X
  • medly Free, same-day prescription delivery to your doorstep is available in your area.
  • Learn more
  • Local Pharmacy Pickup available at . Pick up your medication at any of our participating pharmacies.
  • Mail Order Home Delivery available at , the easiest way to receive your medications.

Perphenazine Coupons & Prices

Set your location
for drug prices near you

Enter your zip code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Perphenazine Drug Information:

Perphenazine is an anti-psychotic medicine in a group of drugs called phenothiazines (FEEN-oh-THYE-a-zeens). It works by changing the actions of chemicals in your brain. Perphenazine is used to treat psychotic disorders such as schizophrenia. It is also used to control severe nausea and vomiting. Perphenazine may also be used for purposes not listed in this medication guide. You should not use perphenazine if you have liver disease, brain damage, bone marrow depression, a blood cell disorder, or if you are also using large amounts of Alcohol or medicines that make you sleepy. Learn more

Buy Perphenazine Online and Perphenazine Delivery

USARx offers the following ways to purchase this medication. Choose the Best option for you!

  • Guaranteed Price

    Local Pharmacy Pickup of Perphenazine

    Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.

  • 30-day supply
    90-day supply

    Mail Order Home Delivery of Perphenazine

    The easiest way to receive your medications.

Perphenazine Side Effects

For the Consumer

Applies to perphenazine: oral fixed-combination tablets, oral tablets

Warning

    Increased Mortality in Geriatric Patients with Dementia-related Psychosis
  • Geriatric patients with dementia-related psychosis treated with antipsychotic agents are at an increased risk of death.

  • Analyses of 17 placebo-controlled trials in geriatric patients mainly receiving atypical antipsychotic agents revealed an approximate 1.6- to 1.7-fold increase in mortality compared with that in patients receiving placebo.

  • Most fatalities appeared to result from cardiovascular-related events (e.g., heart failure, sudden death) or infections (mostly pneumonia).

  • Observational studies suggest that conventional or first-generation antipsychotic agents also may increase mortality in such patients.

  • Antipsychotic agents, including perphenazine, are not approved for the treatment of dementia-related psychosis.

Side effects include:

Extrapyramidal reactions (e.g., Parkinson-like symptoms, dystonia, akathisia, tardive dyskinesia), drowsiness, muscular weakness, dry mouth, blurred vision, weight gain, skin reactions, amenorrhea, galactorrhea.

For Healthcare Professionals

Applies to perphenazine: compounding powder, injectable solution, oral concentrate, oral tablet

Nervous system

Frequency not reported: Extrapyramidal symptoms, opisthotonos, motor restlessness, hyperreflexia, dystonia, slurred speech, akathisia, dyskinesia, parkinsonism, ataxia, drowsiness, sedation, hypnosis, lethargy, cerebral edema, convulsive seizures, hyperactivity

Postmarketing reports: Headaches, choreiform movements of the extremities, orofacial dyskinesia, tardive dyskinesia, disturbances in consciousness, somnolence, stupor, dizziness, tremor, epileptic fits, neuroleptic malignant syndrome (NMS), severe extrapyramidal dysfunction, coma, autonomic disturbances, cerebrospinal fluid protein abnormalities

Convulsive seizures occurred most frequently in patients with EEG abnormalities and/or patients with a history of convulsive seizures.

Drowsiness usually occurred within the first 1 to 2 weeks, with gradual disappearance thereafter.

NMS occurred in patients who took neuroleptic drugs, and was fatal in some cases. NMS was characterized by severe extrapyramidal dysfunction, rigidity, stupor, coma, hyperthermia, and/or autonomic disturbances.

Significant autonomic effects were infrequently reported in patients who received less than 24 mg/day.

Cardiovascular

Frequency not reported: Pallor, hypertension, change in pulse rate, circulatory collapse, postural hypotension, bradycardia, peripheral edema, shock-like condition (hypotensive effect), reversible and nonspecific ECG changes

Postmarketing reports: Tachycardia, QT prolongation, ventricular arrhythmias, ventricular tachycardia/fibrillation, edema, cardiovascular effects (related to neuroleptic malignant syndrome), hypotension, venous thromboembolism, deep vein thrombosis, cardiac arrest and Torsades de pointes

Tachycardia occurred more commonly with sudden, marked increases in dose.

Dermatologic

Frequency not reported: Perspiration, urticaria, erythema, eczema, exfoliative dermatitis, photosensitivity, angioneurotic edema, contact dermatitis, skin pigmentation (in exposed areas)

Postmarketing reports: Photosensitivity, rashes/pruritus, hyperhidrosis

Contact dermatitis occurred in nursing personnel who handled the drug.

Gastrointestinal

Frequency not reported: Nausea, dysphagia, vomiting, diarrhea, obstipation, fecal impaction, parotid swelling, protrusion/discoloration/aching and rounding of tongue,

Postmarketing reports: Oral dryness and altered saliva, adynamic ileus, constipation, other gastrointestinal atonic and hypomotility disorders

Musculoskeletal

Frequency not reported: Trismus, torticollis, retrocollis, aching and numbness of limbs, tonic spasm of masticatory muscles, muscle weakness, prolonged abnormal contractions of muscle groups

Postmarketing reports: Systemic lupus erythematosus (SLE)/SLE-like syndrome, rigidity

Ocular

Frequency not reported: Oculogyric crisis, myosis, mydriasis, glaucoma, photophobia, epithelial keratopathies

Postmarketing reports: Visual disorders, blurred vision, pigmented/pigmentary retinopathy, star-shaped lenticular opacities, fine particulate matter deposits in the cornea and lens

Psychiatric

Frequency not reported: Exacerbation of psychotic symptoms, catatonia/catatonic-like states, paranoid reactions, nocturnal confusion, bizarre dreams, libido changes,

Postmarketing reports: Confusion, agitation, excitement, insomnia

Hematologic

Frequency not reported: Blood dyscrasias, eosinophilia, leukopenia, hemolytic anemia, thrombocytopenic purpura, pancytopenia

Postmarketing reports: Agranulocytosis, transient leukopenia

Metabolic

Frequency not reported: Anorexia, hypoglycemia, polyphagia, increased appetite

Postmarketing reports: Weight gain, hyperglycemia, increased serum cholesterol

Respiratory

Frequency not reported: Throat tightness, asthma, laryngeal edema

Postmarketing reports: Nasal stuffiness, pulmonary embolism

Other

Frequency not reported: Fever/hyperpyrexia, reversed epinephrine effect

Postmarketing reports: Fatigue, body temperature dysregulation, hyperthermia, sudden unexplained death, neonatal drug withdrawal syndrome

Endocrine

Frequency not reported: Syndrome of inappropriate antidiuretic hormone (ADH) secretion, protein bound iodine (PBI) increase not attributable to an increase in thyroxine

Postmarketing reports: Hyperprolactinemia, gynecomastia (males), false positive pregnancy tests

Hepatic

Frequency not reported: Liver damage/biliary stasis, infectious hepatitis

Postmarketing reports: Obstructive jaundice, cholestasis and chronic jaundice

Hypersensitivity

Frequency not reported: Anaphylactoid reactions

Renal

Frequency not reported: Glycosuria

Genitourinary

Postmarketing reports: Urinary hesitancy/retention/incontinence, amenorrhea, erectile dysfunction, impaired ejaculation, lactation, galactorrhea, moderate breast enlargement (females), bladder paralysis, polyuria, menstruation with decreased bleeding or disturbances in the menstrual cycle

Immunologic

Postmarketing reports: Antinuclear antibodies

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Perphenazine (www.drugs.com/mtm/perphenazine.html).